Statements (48)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquisition |
Actavis (2016)
|
| gptkbp:ceo |
gptkb:Kåre_Schultz
|
| gptkbp:employees |
over 40,000
|
| gptkbp:founded |
1901
|
| gptkbp:founder |
Salomon, Meir
|
| gptkbp:global_presence |
operates in over 60 countries
|
| gptkbp:headcount |
approximately 38,000 (2021)
|
| gptkbp:headquarters |
Petah Tikva, Israel
|
| https://www.w3.org/2000/01/rdf-schema#label |
Teva Pharmaceuticals
|
| gptkbp:industry |
gptkb:pharmaceuticals
|
| gptkbp:market |
global
|
| gptkbp:partnership |
various biotech companies
|
| gptkbp:product_line |
antibiotics
vaccines hormonal therapies respiratory medications oncology drugs over-the-counter products psychiatric medications cardiovascular drugs dermatological products gastrointestinal drugs pain management drugs neurology drugs multiple sclerosis treatments |
| gptkbp:products |
generic drugs
specialty medicines |
| gptkbp:research_and_development |
invests heavily
|
| gptkbp:revenue |
$16.7 billion (2020)
|
| gptkbp:stock_exchange |
gptkb:NYSE
|
| gptkbp:stock_symbol |
gptkb:TEVA
|
| gptkbp:subsidiary |
gptkb:Teva_Canada
gptkb:Teva_Israel gptkb:Teva_Europe gptkb:Teva_USA |
| gptkbp:sustainability_initiatives |
gptkb:supply_chain_management
community engagement ethical business practices product safety research funding innovation in healthcare employee welfare environmental responsibility access to medicines healthcare partnerships |
| gptkbp:bfsParent |
gptkb:Plan_B
|
| gptkbp:bfsLayer |
4
|